Get started
Author

Yoshihiro Umezawa

Observed names: Y Umezawa, Y. Umezawa, YOSHIHIRO UMEZAWA
Observed institutions: Tokyo Medical and Dental University, Kyoto University, Tokyo Metropolitan Komagome Hospital, Ome Municipal General Hospital, Oita University Hospital, Institute of Science Tokyo Hospital, Institute of Science Tokyo
ORCID: 0000-0003-1027-1552
Observed ORCID: 0000-0003-1027-1552
OpenAlex ID: A5002230786
FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia
2015 · Ayako Nogami, Gaku Oshikawa, et al. · Oncotarget · 69
PDF
Risk factors for CAR‐T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan
2023 · Tomoyasu Jo, Satoshi Yoshihara, et al. · British Journal of Haematology · 64
FLT3-ITD Activates RSK1 to Enhance Proliferation and Survival of AML Cells by Activating mTORC1 and eIF4B Cooperatively with PIM or PI3K and by Inhibiting Bad and BIM
2019 · Daisuke Watanabe, Ayako Nogami, et al. · Cancers · 52
PDF
FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway
2017 · Keigo Okada, Ayako Nogami, et al. · Oncotarget · 38
PDF
Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress
2019 · Hiroki Akiyama, Yoshihiro Umezawa, et al. · Cancer Letters · 35
Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2
2018 · Shinya Ishida, Hiroki Akiyama, et al. · Oncotarget · 27
Proliferation and Survival Signaling from Both Jak2-V617F and Lyn Involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 Cell Line Newly Established from Acute Myeloid Leukemia Transformed from Polycythemia Vera
2014 · Toshikage Nagao, Tetsuya Kurosu, et al. · PLoS ONE · 25
PDF
Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis
2023 · Keisuke Tanaka, Ayako Ichikawa, et al. · Cancer Science · 22
PDF
Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study
2022 · Hiroshi Kawabata, Takeshi Tamura, et al. · International Journal of Hematology · 20
PDF
Inhibition of the STAT5/Pim Kinase Axis Enhances Cytotoxic Effects of Proteasome Inhibitors on FLT3-ITD–Positive AML Cells by Cooperatively Inhibiting the mTORC1/4EBP1/S6K/Mcl-1 Pathway
2018 · Ayako Nogami, Keigo Okada, et al. · Translational Oncology · 19
PDF
Clinical features and risk factors for developing varicella zoster virus dissemination following hematopoietic stem cell transplantation
2014 · Y. Umezawa, K. Kakihana, et al. · Transplant Infectious Disease · 19
A novel MYD88 mutation, L265RPP, in Waldenström macroglobulinemia activates the NF-κB pathway to upregulate Bcl-xL expression and enhances cell survival
2015 · T Nagao, G Oshikawa, et al. · Blood Cancer Journal · 18
PDF
Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells
2020 · Hiroki Akiyama, Yoshihiro Umezawa, et al. · Cancers · 17
PDF
Severe Motor Weakness Due to Disturbance in Peripheral Nerves Following Tisagenlecleucel Treatment
2021 · MAI KUBOKI, YOSHIHIRO UMEZAWA, et al. · In Vivo · 14
PDF
Molecular mechanisms for enhancement of stromal cell-derived factor 1–induced chemotaxis by platelet endothelial cell adhesion molecule 1 (PECAM-1)
2017 · Yoshihiro Umezawa, Hiroki Akiyama, et al. · Journal of Biological Chemistry · 11
PDF
Impact of BK polyomavirus viremia on the outcomes of allogeneic hematopoietic stem cell transplantation
2024 · Yoshihiro Umezawa, Kota Yoshifuji, et al. · Annals of Hematology · 8
Down regulation of Chk1 by p53 plays a role in synergistic induction of apoptosis by chemotherapeutics and inhibitors for Jak2 or BCR/ABL in hematopoietic cells
2016 · Yoshihiro Umezawa, Tetsuya Kurosu, et al. · Oncotarget · 7
PDF
A novel chimeric antigen receptor (CAR) system using an exogenous protease, in which activation of T cells is controlled by expression patterns of cell‑surface proteins on target cells
2022 · Satoru Aoyama, Shunichiro Yasuda, et al. · International Journal of Molecular Medicine · 6
PDF
Decreased renal function predicts severe cytokine release syndrome after CAR ‐T‐cell therapy for large B‐cell lymphoma
2026 · Yasuyuki Arai, Tomoyasu Jo, et al. · British Journal of Haematology · 5
An early regulatory mechanism of hyperinflammation by restricting monocyte contribution
2024 · Megumi Akiyama, Masashi Kanayama, et al. · Frontiers in Immunology · 5
Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma
2023 · Yotaro Motomura, Kota Yoshifuji, et al. · British Journal of Haematology · 5
Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia
2022 · Yoshihiro Umezawa, Koji Sasaki · International Journal of Hematology · 5
Methotrexate-associated Classical Hodgkin Lymphoma Shows Distinct Clinicopathological Features but Comparable Clinical Outcomes With Sporadic Cases
2019 · KOTA YOSHIFUJI, YOSHIHIRO UMEZAWA, et al. · In Vivo · 4
PDF
Therapy-related Leukemia with Inv(16)(p13.1q22) and Type D CBFB/MYH11 Developing after Exposure to Irinotecan-containing Chemoradiotherapy
2015 · Hiroki Akiyama, Masahide Yamamoto, et al. · Internal Medicine · 4
PDF
Hepatitis C virus-related hepatitis flare after immunochemotherapy in a patient with follicular lymphoma
2024 · Yotaro Motomura, Kota Yoshifuji, et al. · Journal of the Japan Society of the Reticuloendothelial System · 3
PDF
Works count: 63
Citation count: 526
H-index: 14
I10-index: 15
Year
Topic
Type